<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02226978</url>
  </required_header>
  <id_info>
    <org_study_id>1182.104</org_study_id>
    <nct_id>NCT02226978</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir (TPV/r) With Single-dose Valaciclovir (VAL) in Healthy Volunteers</brief_title>
  <official_title>An Open-label One-sequence Cross-over Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir 500/200 mg With Single-dose Valaciclovir (500 mg) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Assessment of the interaction of tipranavir/ritonavir (TPV/RTV) and valaciclovir (VAL), a&#xD;
      prodrug of aciclovir (ACV)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of aciclovir in plasma over the time interval t0h to t12h (AUC0-12)</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of aciclovir in plasma (Cmax)</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-12 for Tipranavir (TPV)</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for TPV</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug concentration of TPV in plasma at 12 hours after administration (C12h)</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance of the analyte in the plasma after extravascular administration (CL/F)</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F)</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of the analyte in plasma (t1/2)</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant findings in laboratory tests</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-12 for Ritonavir (RTV)</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for RTV</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug concentration of RTV in plasma at 12 hours after administration (C12h)</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>TPV/r with valaciclovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VAL 2 days (on days 1 and 13), TPV/r 12 days (on days 2 to 13)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir</intervention_name>
    <arm_group_label>TPV/r with valaciclovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <arm_group_label>TPV/r with valaciclovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valaciclovir</intervention_name>
    <arm_group_label>TPV/r with valaciclovir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and non-pregnant, non-lactating female subjects as determined by results&#xD;
             of screening&#xD;
&#xD;
          -  Signed written informed consent in accordance with Good Clinical Practice (GCP) and&#xD;
             local legislation&#xD;
&#xD;
          -  The ability to understand and sign a written informed consent form, prior to&#xD;
             participation in any screening procedures and willingness to comply with all study&#xD;
             requirements&#xD;
&#xD;
          -  Age &gt;19 and &lt;59 years (20 - 58 years inclusive)&#xD;
&#xD;
          -  Weight ≥ 60 kg&#xD;
&#xD;
          -  Body mass index (BMI) &gt;18.5 and &lt;29.9 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any finding of the medical examination (including blood pressure, pulse rate, and&#xD;
             electrocardiogram) deviating from normal and of clinical relevance&#xD;
&#xD;
          -  Atrioventricular (AV) block including 1°&#xD;
&#xD;
          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic,&#xD;
             hematological, oncological or hormonal disorders&#xD;
&#xD;
          -  Surgery of gastrointestinal tract (except appendectomy)&#xD;
&#xD;
          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or&#xD;
             neurological disorders&#xD;
&#xD;
          -  Relevant history of orthostatic hypotension, fainting spells or blackouts&#xD;
&#xD;
          -  Chronic or relevant acute infections&#xD;
&#xD;
          -  History of allergy/hypersensitivity (including drug allergy) which is deemed relevant&#xD;
             to the trial as judged by the investigator&#xD;
&#xD;
          -  Known hypersensitivity to TPV, RTV, valaciclovir, aciclovir or antiretroviral drugs&#xD;
             (marketed or experimental use as part of clinical research studies)&#xD;
&#xD;
          -  Known elevated liver enzymes in past trials with any compound&#xD;
&#xD;
          -  Intake of drugs with a long half-life (&gt;24 hours) (&lt;1 month prior to administration)&#xD;
&#xD;
          -  Prescription or over the counter medications (including vitamins, minerals, herbal&#xD;
             supplements and antacids), dietary supplements 14 days prior to study drug&#xD;
             administration or expected during the trial)&#xD;
&#xD;
          -  Participation in another trial with an investigational drug (&lt;2 months prior to&#xD;
             administration or expected during trial)&#xD;
&#xD;
          -  Smoker with a consumption of &gt;10 cigarettes or &gt;3 cigars or &gt;3 pipes/day and those who&#xD;
             cannot keep tobacco intake constant&#xD;
&#xD;
          -  Alcohol (&gt;40 g/day for males and &gt;20 g/day for females) and drug abuse&#xD;
&#xD;
          -  Blood donation or loss &gt;400 mL, &lt; 3 month prior to administration&#xD;
&#xD;
          -  Clinically relevant laboratory abnormalities&#xD;
&#xD;
          -  Transaminases above reference values in the history&#xD;
&#xD;
          -  Inability to comply with dietary regimen of study centre&#xD;
&#xD;
        For female subjects:&#xD;
&#xD;
          -  Pregnancy or planning to become pregnant within 60 days of study completion&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  Have not been using a barrier method of contraception for at least 3 months prior to&#xD;
             participation in the study if of childbearing potential and not surgically sterilized&#xD;
&#xD;
          -  Are not willing or are unable to use a reliable method of barrier contraception (such&#xD;
             as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during&#xD;
             and up to 2 months after completion/termination of the trial if of childbearing&#xD;
             potential and not surgically sterilized&#xD;
&#xD;
          -  Chronic use of oral contraception or hormone replacement containing ethinyl estradiol&#xD;
&#xD;
          -  Breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>58 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>August 26, 2014</study_first_submitted>
  <study_first_submitted_qc>August 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2014</study_first_posted>
  <last_update_submitted>August 26, 2014</last_update_submitted>
  <last_update_submitted_qc>August 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
    <mesh_term>Valacyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

